Victory Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Victory Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,446	Closed	-$334K	–	3484
2020 Q1	$334K	Sell	4,446 -149	-3%	-$14.2K	﹤0.01%	1986
2019 Q4	$373K	Sell	4,595 -182	-4%	-$20.4K	﹤0.01%	2131
2019 Q3	$583K	Buy	4,777 +1,576	+49%	+$217K	﹤0.01%	1835
2019 Q2	$575K	Sell	3,201 -1,168	-27%	-$189K	﹤0.01%	1357
2019 Q1	$699K	Sell	4,369 -44	-1%	-$8.71K	﹤0.01%	1298
2018 Q4	$1.15M	Sell	4,413 -76	-2%	-$15.3K	﹤0.01%	1182
2018 Q3	$1.09M	Sell	4,489 -244	-5%	-$63.9K	﹤0.01%	1255
2018 Q2	$1.12M	Buy	+4,733	New	+$1.38M	﹤0.01%	1229

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Victory Capital Management's EVLO Position: Q2 2020 in Review

Victory Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2020, closing a stake of 4,446 shares — an estimated $334K sold.

Victory Capital Management first reported a position in EVLO in Q2 2018 and held it in 8 quarters. The position peaked at $1.15M in Q4 2018. 47 funds tracked by Wall St. Rank hold EVLO as of Q2 2020.

Victory Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Victory Capital Management sold 4,446 Evelo Biosciences, Inc. Common Stock shares in Q2 2020, an estimated $334K.
Victory Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Victory Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $1.15M in Q4 2018.
47 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.